Butyrate Histone Deacetylase Inhibitors

Abstract In addition to being a part of the metabolic fatty acid fuel cycle, butyrate is also capable of inducing growth arrest in a variety of normal cell types and senescence-like phenotypes in gynecological cancer cells, inhibiting DNA synthesis and cell growth in colonic tumor cell lines, suppressing hTERT mRNA expression and telomerase activity in human prostate cancer cells, and inducing stem cell differentiation and apoptosis by DNA fragmentation. It regulates gene expression by inhibiting histone deacetylases (HDACs), enhances memory recovery and formation in mice, stimulates neurogenesis in the ischemic brain, promotes osteoblast formation, selectively blocks cell replication in transformed cells (compared to healthy cells), and can prevent and treat diet-induced obesity and insulin resistance in mouse models of obesity, as well as stimulate fetal hemoglobin expression in individuals with hematologic diseases such as the thalassemias and sickle-cell disease, in addition to a multitude of other biochemical effects in vivo. However, efforts to exploit the potential of butyrate in the clinical treatment of cancer and other medical disorders are thwarted by its poor pharmacological properties (short half-life and first-pass hepatic clearance) and the multigram doses needed to achieve therapeutic concentrations in vivo. Herein, we review some of the methods used to overcome these difficulties with an emphasis on HDAC inhibition.

[1]  C. Pinkert,et al.  Protection by an antioxidant of rotenone-induced neuromotor decline, reactive oxygen species generation and cellular stress in mouse brain , 2012, Pharmacology Biochemistry and Behavior.

[2]  A. Nudelman,et al.  A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  I. Goethals,et al.  In vitro 2-deoxy-2-[18F]fluoro-D-glucose uptake: practical considerations. , 2012, Cancer biotherapy & radiopharmaceuticals.

[4]  Udayanath Aich,et al.  Metabolic oligosaccharide engineering with N‐Acyl functionalized ManNAc analogs: Cytotoxicity, metabolic flux, and glycan‐display considerations , 2012, Biotechnology and bioengineering.

[5]  P. Jagodziński,et al.  Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  A. Basu,et al.  Epigenetic regulation of self‐renewal and fate determination in neural stem cells , 2012, Journal of neuroscience research.

[7]  R. Berni Canani,et al.  The epigenetic effects of butyrate: potential therapeutic implications for clinical practice , 2012, Clinical Epigenetics.

[8]  Robert M. Williams,et al.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. , 2012, Blood.

[9]  M. Sun,et al.  Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. , 2012, Genetics and molecular research : GMR.

[10]  P. Mali,et al.  Concise Review: Human Cell Engineering: Cellular Reprogramming and Genome Editing , 2012, Stem cells.

[11]  D. Hadjipavlou-Litina,et al.  Histone deacetylase inhibitors (HDACIs). Structure—activity relationships: history and new QSAR perspectives , 2012, Medicinal research reviews.

[12]  R. Grundy,et al.  Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy , 2011, International journal of cancer.

[13]  R. Machado-Vieira,et al.  Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene‐Environment Interactions , 2011, CNS neuroscience & therapeutics.

[14]  F. Crea,et al.  Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[15]  S. Bates,et al.  Histone deacetylase inhibitors: emerging mechanisms of resistance. , 2011, Molecular pharmaceutics.

[16]  X. Coumoul,et al.  Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex , 2011, International journal of cancer.

[17]  David E. Williams,et al.  Metabolism as a key to histone deacetylase inhibition , 2011, Critical reviews in biochemistry and molecular biology.

[18]  P. Bertrand,et al.  Interpreting clinical assays for histone deacetylase inhibitors. , 2011, Cancer management and research.

[19]  Jennifer J Westendorf,et al.  Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.

[20]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[21]  Anthony E. Boitano,et al.  Chemical control of stem cell fate and developmental potential. , 2011, Angewandte Chemie.

[22]  C. Pinkert,et al.  D-galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. , 2010, Rejuvenation research.

[23]  Nessa Carey,et al.  Epigenetic therapies for non-oncology indications. , 2010, Drug discovery today.

[24]  D. Faller,et al.  A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers , 2010, British journal of haematology.

[25]  E. Lam,et al.  Butyrate-rich Colonic Microenvironment Is a Relevant Selection Factor for Metabolically Adapted Tumor Cells* , 2010, The Journal of Biological Chemistry.

[26]  D. Faller,et al.  Fetal globin gene inducers: novel agents and new potential , 2010, Annals of the New York Academy of Sciences.

[27]  H. Fang,et al.  Strategies in developing promising histone deacetylase inhibitors , 2010, Medicinal research reviews.

[28]  Yi Zhang,et al.  Butyrate Promotes Induced Pluripotent Stem Cell Generation* , 2010, The Journal of Biological Chemistry.

[29]  Ying Sun,et al.  Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. , 2010, Chemico-biological interactions.

[30]  E. Ho,et al.  Dietary Manipulation of Histone Structure and Function , 2010, Lifestyle Genomics.

[31]  S. Baylin,et al.  Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency‐Associated Genes , 2010, Stem cells.

[32]  R. Wanders,et al.  A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation , 2010, Journal of Inherited Metabolic Disease.

[33]  Jeffrey Perkel Histone code-breakers: the technologies of an epigenetic enigma. , 2010, BioTechniques.

[34]  Yixue Li,et al.  Regulation of Cellular Metabolism by Protein Lysine Acetylation , 2010, Science.

[35]  S. McMahon,et al.  Rise of the Rival , 2010, Science.

[36]  Delong Liu,et al.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.

[37]  J. Cueva,et al.  Novel therapeutic approaches to the treatment of metastatic breast cancer. , 2010, Cancer treatment reviews.

[38]  Robert M. Williams,et al.  Discovery, Biological Activity, Synthesis and Potential Therapeutic Utility of Naturally Occurring Histone Deacetylase Inhibitors , 2010 .

[39]  P. Seeberger,et al.  Carbohydrates: A Frontier in Medicinal Chemistry , 2009 .

[40]  Qi-Long Ying,et al.  Differentiation of mouse embryonic stem cells into hepatocytes induced by a combination of cytokines and sodium butyrate , 2009, Journal of cellular biochemistry.

[41]  T. Enver,et al.  Forcing cells to change lineages , 2009, Nature.

[42]  M. A. Meledeo,et al.  Hexosamine analogs: from metabolic glycoengineering to drug discovery. , 2009, Current opinion in chemical biology.

[43]  D. Wagner,et al.  The stem cell--chromatin connection. , 2009, Seminars in cell & developmental biology.

[44]  K. Kang,et al.  Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells , 2009, Cell proliferation.

[45]  Shu-Chen Lu,et al.  Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity , 2009, Chemical biology & drug design.

[46]  C. Hoppel,et al.  Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? , 2009, Advanced drug delivery reviews.

[47]  Haishan Wang,et al.  New patented histone deacetylase inhibitors , 2009, Expert opinion on therapeutic patents.

[48]  Danny Reinberg,et al.  Histones: annotating chromatin. , 2009, Annual review of genetics.

[49]  M. Morgan,et al.  A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. , 2009, Chemical communications.

[50]  S. McMahon,et al.  Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells. , 2009, Trends in biochemical sciences.

[51]  E. Levy,et al.  In vitro studies on the inhibition of colon cancer by butyrate and carnitine. , 2009, Nutrition.

[52]  D. Faller,et al.  Lactic acid in cancer and mitochondrial disease , 2009 .

[53]  J. Workman,et al.  Introducing the acetylome , 2009, Nature Biotechnology.

[54]  L. Monteggia,et al.  Synergistic Interactions between Histone Deacetylase Inhibitors and Drugs of Abuse , 2009, Neuropsychopharmacology.

[55]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[56]  J. Buggy,et al.  Isoform-specific histone deacetylase inhibitors: the next step? , 2009, Cancer letters.

[57]  D. Chuang,et al.  The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain , 2009, Journal of neurochemistry.

[58]  Xue-Long Sun,et al.  Recent developments in carbohydrate‐decorated targeted drug/gene delivery , 2009, Medicinal research reviews.

[59]  K. Yelekçi,et al.  Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. , 2009, Bioorganic & medicinal chemistry.

[60]  N. Habermann,et al.  Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. , 2009, Mutation research.

[61]  Michael Bots,et al.  Rational Combinations Using HDAC Inhibitors , 2009, Clinical Cancer Research.

[62]  E. Purgatto,et al.  Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug , 2009, International journal of cancer.

[63]  D. Faller,et al.  Erythroid Kruppel‐like factor (EKLF) is recruited to the γ‐globin gene promoter as a co‐activator and is required for γ‐globin gene induction by short‐chain fatty acid derivatives , 2009, European journal of haematology.

[64]  L. Altucci,et al.  Histone acetyltransferase inhibitors and preclinical studies , 2009, Expert opinion on therapeutic patents.

[65]  M. Rowley,et al.  Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. , 2009, Journal of medicinal chemistry.

[66]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[67]  Robert Brown,et al.  The promises and pitfalls of epigenetic therapies in solid tumours. , 2009, European journal of cancer.

[68]  Raja R Srinivas,et al.  Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. , 2009, Journal of medicinal chemistry.

[69]  W. Cefalu,et al.  Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice , 2009, Diabetes.

[70]  R. Marino,et al.  Probiotic in lamb rennet paste enhances rennet lipolytic activity, and conjugated linoleic acid and linoleic acid content in Pecorino cheese. , 2009, Journal of dairy science.

[71]  W. Ma,et al.  Novel Agents on the Horizon for Cancer Therapy , 2009, CA: a cancer journal for clinicians.

[72]  Ivars Kalvinsh,et al.  Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. , 2009, European journal of medicinal chemistry.

[73]  Zhihong Zhang,et al.  Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software. , 2009, Journal of proteome research.

[74]  A. Munshi,et al.  Histone modifications dictate specific biological readouts. , 2009, Journal of genetics and genomics = Yi chuan xue bao.

[75]  C. Chaumontet,et al.  Butyrate metabolism in human colon carcinoma cells: Implications concerning its growth‐inhibitory effect , 2009, Journal of cellular physiology.

[76]  Udayanath Aich,et al.  Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. , 2008, Journal of medicinal chemistry.

[77]  Christopher E. Berndsen,et al.  Catalysis and substrate selection by histone/protein lysine acetyltransferases. , 2008, Current opinion in structural biology.

[78]  Michael J. Meaney,et al.  Diet and the epigenetic (re)programming of phenotypic differences in behavior , 2008, Brain Research.

[79]  Brian C. Smith,et al.  Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.

[80]  D. Schrenk,et al.  Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. , 2008, The Journal of nutritional biochemistry.

[81]  M. Addis,et al.  The use of lamb rennet paste in traditional sheep milk cheese production , 2008 .

[82]  Wenfang Xu,et al.  Synthesis of Carnitine Benzyl Esters as Prodrugs , 2008 .

[83]  A. Nudelman,et al.  Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex) , 2008, Clinical & Experimental Metastasis.

[84]  E. Ferreira,et al.  Prodrugs for the Treatment of Neglected Diseases , 2008, Molecules.

[85]  O. Piermatti,et al.  Synthesis and characterization of carnitine nitro-derivatives. , 2008, Bioorganic & medicinal chemistry.

[86]  Joshua Close,et al.  Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). , 2008, Bioorganic & medicinal chemistry letters.

[87]  M. Egorin,et al.  Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[88]  Melissa Chenard,et al.  Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). , 2008, Bioorganic & medicinal chemistry letters.

[89]  V. Ganapathy,et al.  Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[90]  Yukihiro Itoh,et al.  Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.

[91]  E. Ho,et al.  Dietary histone deacetylase inhibitors: from cells to mice to man. , 2007, Seminars in cancer biology.

[92]  T. Beckers,et al.  2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. , 2007, Journal of medicinal chemistry.

[93]  Yi Tang,et al.  Lysine Propionylation and Butyrylation Are Novel Post-translational Modifications in Histones*S , 2007, Molecular & Cellular Proteomics.

[94]  M. K. Pflum,et al.  Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. , 2007, Bioorganic & medicinal chemistry letters.

[95]  D. Riester,et al.  Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases , 2007, Applied Microbiology and Biotechnology.

[96]  C. Klein,et al.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.

[97]  K. Yarema,et al.  Metabolic oligosaccharide engineering: perspectives, applications, and future directions. , 2007, Molecular bioSystems.

[98]  M. A. Meledeo,et al.  Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. , 2006, Chemistry & biology.

[99]  D. Faller,et al.  Identification of Novel Small‐molecule Inducers of Fetal Hemoglobin Using Pharmacophore and ‘PSEUDO’ Receptor Models , 2006, Chemical biology & drug design.

[100]  V. Ganapathy,et al.  SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. , 2006, Life sciences.

[101]  K. Gilbert,et al.  Structure-activity relationship between carboxylic acids and T cell cycle blockade. , 2006, Life sciences.

[102]  A. Nudelman,et al.  The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs , 2006, Investigational New Drugs.

[103]  S. Vandenberg,et al.  Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.

[104]  D. Faller,et al.  Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. , 2005, Blood cells, molecules & diseases.

[105]  C. Chen,et al.  Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. , 2005, Journal of medicinal chemistry.

[106]  C. Monneret Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[107]  Steven Jupe,et al.  A family of fatty acid binding receptors. , 2005, DNA and cell biology.

[108]  R. Cecchelli,et al.  Carnitine: transport and physiological functions in the brain. , 2004, Molecular aspects of medicine.

[109]  Steven J. Miller Cellular and physiological effects of short-chain fatty acids. , 2004, Mini reviews in medicinal chemistry.

[110]  O. Witt,et al.  Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. , 2003, Blood.

[111]  B. Pace,et al.  Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. , 2002, Blood.

[112]  S. Horiuchi,et al.  Sodium butyrate induces growth arrest and senescence‐like phenotypes in gynecologic cancer cells , 2001, International journal of cancer.

[113]  S. Sampson,et al.  Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. , 2001, European journal of medicinal chemistry.

[114]  B. Pace,et al.  Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. , 2001, Blood.

[115]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[116]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[117]  G. Stamatoyannopoulos,et al.  Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. , 1999, Blood.

[118]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[119]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[120]  L. Bieber,et al.  Possible functions of short-chain and medium-chain carnitine acyltransferases. , 1982, Federation proceedings.

[121]  F. Knoop The Degradation of Aromatic Fatty Acids in the Animal Body , 1968 .

[122]  Honglin Jiang,et al.  Butyrate activates the cAMP-protein kinase A-cAMP response element-binding protein signaling pathway in Caco-2 cells. , 2012, The Journal of nutrition.

[123]  Antonio Calignano,et al.  Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. , 2011, World journal of gastroenterology.

[124]  M. Eisenstein IPSCs: One cell to rule them all? , 2010, Nature Methods.

[125]  D. Wallace,et al.  Energetics, epigenetics, mitochondrial genetics. , 2010, Mitochondrion.

[126]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Natalie de Souza Primer: induced pluripotency. , 2010, Nature methods.

[128]  Stephan Beck,et al.  Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. , 2009, The international journal of biochemistry & cell biology.

[129]  V. Ganapathy,et al.  Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. , 2009, The Biochemical journal.

[130]  Sama F. Sleiman,et al.  Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. , 2009, Expert opinion on investigational drugs.

[131]  V. Ganapathy,et al.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.

[132]  Lucia Altucci,et al.  Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. , 2009, The international journal of biochemistry & cell biology.

[133]  Udayanath Aich,et al.  Non-Natural Sugar Analogues: Chemical Probes for Metabolic Oligosaccharide Engineering , 2008 .

[134]  B. Gajkowska,et al.  Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. , 2007, Advances in medical sciences.

[135]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[136]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[137]  S. Perrine Fetal Globin Induction—Can It Cure β Thalassemia? , 2005 .

[138]  Mark B. Jones,et al.  Establishment of N‐Acetylmannosamine (ManNAc) Analogue‐Resistant Cell Lines as Improved Hosts for Sialic Acid Engineering Applications , 2004, Biotechnology progress.

[139]  寺尾 泰久 Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells , 2002 .